Clinical trial data suggests that tirzepatide (Mounjaro) produces greater average weight loss at its highest studied doses than semaglutide 2.4 mg (Wegovy)
Many patients reduce their total food intake by 4060% during the first months of treatment, which directly lowers intake of these essential compounds
Supplementary Information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
The typical treatments available offer immune system suppression without addressing the inflammatory triggers
The most frequently reported adverse effects of tirzepatide are gastrointestinal in nature, consistent with the GLP-1 receptor agonist class of medications
Modified escalation schedules in units If standard escalation causes intolerable nausea, providers often slow the process
